https://www.selleckchem.com/products/bv-6.html
ICI treatment. Patients with PD-L1-positive tumor could gain more survival benefits from immune checkpoint therapy. Metastatic breast cancer had modest response to ICI therapy. PD-L1-positive, first-line immunotherapy, non-liver metastasis, and high TIL and CD8+ T-cell infiltrating levels could predict better response to ICI treatment. Patients with PD-L1-positive tumor could gain more survival benefits from immune checkpoint therapy. The aim of this study is to evaluate the impact of diabetes, hypertension, cardiovascular disease and the
Like
Comment
Share
